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B-cell chronic lymphocytic leukaemia (B-CLL) remains an incurable disease due to the high risk of relapse, even after complete
remission, raising the need to control and eliminate residual tumor cells in long term. Adoptive T cell therapy with genetically
engineered speciﬁcity is thought to fulﬁl expectations, and clinical trials for the treatment of CLL are initiated. Cytolytic T cells
frompatientsareredirectedtowardsCLLcellsbyexvivoengineeringwithachimericantigenreceptor(CAR)whichbindstoCD19
on CLL cells through an antibody-derived domain and triggers T cell activation through CD3ζ upon tumor cell engagement.
Redirected T cells thereby target CLL cells in an MHC-unrestricted fashion, secret proinﬂammatory cytokines, and eliminate
CD19+ leukaemia cells with high eﬃciency. Cytolysis of autologous CLL cells by patient’s engineered T cells is eﬀective, however,
accompanied by lasting elimination of healthy CD19+ B-cells. In this paper we discuss the potential of the strategy in the treatment
of CLL, the currently ongoing trials, and the future challenges in the adoptive therapy with CAR-engineered T cells.
1.Introduction
B-cell chronic lymphocytic leukaemia (B-CLL) is the most
common leukaemia in the western hemisphere with escalat-
ing incidence. Although treatment of B-CLL has achieved
signiﬁcant progress during the last years based on the use
of nucleoside analoga, monoclonal antibodies, and bone
marrow transplantation [1–5], the disease is rarely cured,
even in those patients with complete molecular remission
[6–8]. Interest is therefore growing in activating the immune
system, by single agents or in combination with chemother-
apy, to control the disease. The application of monoclonal
antibodies, including anti-CD20 and anti-CD52 antibodies,
substantially improved response rates and progression-free
survival [9]. Allogeneic haematopoietic stem cell transplan-
tation induced a signiﬁcant T cell-mediated graft-versus-
leukemia response and durable remissions in a subset
of patients with chemotherapy-refractory B-CLL [4, 5].
Genetically modiﬁed malignant cells enhanced the anti-
tumor response [10, 11]. The isolation of B-CLL-reactive
T cells from patients with long-lasting tumor regression
[12] sustained the concept that adoptive cell therapy with
CLL speciﬁc T cells may be successful in controlling the
disease. Advances in genetic engineering of a recombinant
T cell receptor (TCR) and of a chimeric antigen receptor
(CAR) provide the technology to modify T cells ex vivo with
predeﬁned speciﬁcity for use in speciﬁc cell therapy. This
paper summarizes recent experiences with CAR-engineered
T cells for the use in adoptive therapy of B-CLL.
2.RedirectingT Cellstowards B-CLL
Tumor-speciﬁc T cells can be genetically engineered in large
quantities by engrafting with a recombinant TCR or alterna-
tively with a CAR of predeﬁned tumor speciﬁcity. In contrast
to the TCR, the CAR consists of one trans-membrane
polypeptide chain; the extracellular domain is composed of a
single chain fragment of variable region (scFv) antibody for
binding; the intracellular domain provides T cell activation2 Advances in Hematology
through the CD3ζ endodomain upon antigen engagement
[13–15]. The “T-body” concept thereby combines the power
of the targeting antibody with the eﬀector mechanisms of
cytolytic T cells [14, 16]. The CD3ζ molecule contains three
immunoreceptor tyrosine-based activation motifs (ITAMs)
which are phosphorylated to initiate T cell activation; the
ﬁrst and third ITAMs additionally cause apoptosis. Inacti-
vation of these ITAMs by mutation consequently decreased
apoptosis and enhanced survival of redirected T cells upon
CAR signalling [17–19]. By using an antibody for target
recognition, CAR-redirected T cells bypass the MHC haplo-
types of the individual patients and undergo T cell activation
in an MHC-unrestricted fashion. CAR-modiﬁed T cells can
thereby be redirected towards antigens of various structure
andcomposition.Alternatively,Tcellscanberedirectedinan
MHC-restricted fashion by using antibody-derived binding
domains with TCR-like speciﬁcity [20–22]. Genetically engi-
neered with a CAR, modiﬁed T cells are ampliﬁed ex vivo to
numbers suitable for adoptive cell therapy and administered
to the patient upon preconditioning. Preclinical and clinical
data,whicharediscussedbelow,providestrongevidencethat
peripheralbloodTcellsfromB-CLLpatientscansuccessfully
be redirected to initiate an eﬀective antitumor response even
in advanced stages of the disease.
Success of adoptive therapy with modiﬁed T cells, how-
ever, depends upon eﬃcient and durable expression of the
transgenic CAR. Mostly murine γ-retroviral vectors are used
to modify T cells taking advantage of its small size, stable
transgene integration, and the ability to generate vector
batches of high titres. Up to 1010 gene-modiﬁed T cells can
be obtained by retroviral transduction in a Good Manufac-
toring Procedure-conform manner. However, the strong
mitogenic stimulus required for retrovirus transduction may
result in T cells which have undergone excessive replica-
tion and are suboptimal for an eﬃcient anticancer response.
Lentiviral vectors, in contrast, require cytokine prestimula-
tion of recipient cells which generates T cells with a less
diﬀerentiated phenotype. Recent developments such as the
incorporation of a measles virus envelope protein into viral
particles allow transductions with less or without T cell
stimulation. Alternatively, naked plasmid DNA or RNA by
electroporation is used to obtain CAR-modiﬁed T cells;
the DNA transfection eﬃciency is low requiring exten-
sive T cell ampliﬁcation prior-clinical application. Recent
developments in transposon technology suggest that these
technologies may also be amenable to clinically modifying
T cells in the near future.
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TCellAttackofB-CLLCells
The target for CAR-mediated tumor cell recognition is
crucial for the therapeutic success, and several issues have
to be considered. The target must be expressed on the cell
surface of the tumor cell to be recognized by CAR-modiﬁed
T cells. Most “tumor-associated antigens”, however, are self-
antigens and not exclusively expressed on tumor cells but
on cells of healthy tissues as well. Malignant cells moreover
show extreme ﬂexibility, loose target antigen expression, and
thetumormayrecoverdespiteanongoingimmuneresponse.
Ideal would therefore be a target molecule which is causally
associated with the malignant phenotype since antigen-loss
tumor cell variants which are not furthermore recognized
by CAR-redirected T cells would loose their malignancy and
enter senescence.
ToselectivelytargetB-CLLcells,CD19seemstobeagood
target since it fulﬁls some although not all of the above-cited
criteria. CD19 is physiologically expressed on B-lineage cells
of almost all stages, from the pro-B-cell to mature B-cell, and
is in particular absent from plasma cells, hematopoietic stem
cells and other tissues. CD19 decreases the threshold for B-
cell activation by assembling with the antigen receptor which
enables B-cells to respond to diﬀerent antigens in a speciﬁc
and sensitive manner. B-lineage leukemia cells including B-
CLL express CD19 at high levels, even during progression of
the disease. Targeting CD19 is therefore ideal for redirected
therapy of B-CLL, and no myelosuppression, apart from B-
cell depletion, or other organ toxicities is expected due to the
restricted CD19 expression. CD20 is expressed by nearly the
same cells as CD19; targeting CD20 may be an alternative,
however, with the same expected side eﬀects.
The receptor tyrosine kinase-like orphan receptor 1
(ROR1) may be an alternative target for eliminating B-CLL
cells [23]. Compared to CD19, ROR1 has the advantage that
it is not expressed on normal B-cells. ROR1 is an oncofetal
antigen and expressed by undiﬀerentiated embryonic stem
cells but not by major adult tissues apart from low levels in
adipose tissue and at an early stage of B-cell development.
CAR-modiﬁed T cells with speciﬁcity for ROR1 eliminate B-
CLL cells but not mature normal B-cells. The expression on
some normal tissues, however, suggests potential toxicity of
ROR1-speciﬁc T cells.
4.The CARRedirectedTCellAntitumor
Response Beneﬁts from Costimulation
According to the “two-signal paradigm,” T cells require in
addition to the TCR/CD3 signal (“signal 1”) a second signal
called costimulation or “signal 2” to sustain pro-longed acti-
vation, to improve proliferation, to increase cytokine secre-
tion, and to avoid anergy. CD28 costimulation increases bcl-
2 andbcl-xL expression [24] and thereby improves resistance
towards activation-induced cell death by preventing apop-
tosis. To provide CD28 costimulation along with CAR sig-
nalling,theCD3ζ endodomainwascombinedwiththeCD28
costimulatory domain in a so-called “second generation”
CAR with combined CD28-CD3ζ signalling moiety [25, 26].
There is increasing support for the use of alternative costim-
ulation, for example, via 4-1BB (CD137) or OX40 (CD134),
both members of the CD28 family. Each of these costimula-
torydomainsmodulatestheredirectedeﬀectorfunctionsina
diﬀerent fashion including cytokine secretion, proliferation,
and prevention from activation-induced cell death [27, 28].
CD28 costimulation mediates IL-2 secretion [26, 29, 30];
without simultaneous costimulation through the native B7-
CD28, 4-1BB, and OX40 costimulation do not induce IL-
2 although both increasing IFN-γ secretion. CD28-CD3ζ
CAR stimulated T cells thereby indirectly increase antitumorAdvances in Hematology 3
eﬃcacy by sustaining survival, proliferation, and recruiting
other activated bystander T cells in the tumor environment.
OX40 and 4-1BB costimulation, however, is superior in
preventing activation-induced cell death and in sustaining
T cell survival. These observations lead to CARs with two
costimulatory domains to further improve T cell potency
and persistence by augmenting the levels of anti-apoptotic
proteins [31]. Combining CD28, OX40 and CD3ζ as well
as CD28 with 4-1BB and CD3ζ induced superior T cell
expansion and cytokine secretion. 4-1BB-CD3ζ alone, how-
ever, is superior in antileukaemia activity in vivo compared
to CD28-CD3ζ or CD28-OX40-CD3ζ CARs [32]. CAR-
mediated T cell cytotoxicity as revealed by in vitro short-
term assays, however, is independent of costimulation. Taken
together combining costimulatory domains with CD3ζ
allows for speciﬁcally modulating T cell eﬀector functions in
order to sustain a long-lasting antitumor response.
Costimulation, moreover, provides beneﬁt when T cells
enter the immune-suppressive environment of tumors. Im-
mune repression, mostly more pronounced in solid tumors,
is mediated inﬁltrating suppressive cells and by tumor cells
itself through repressive cytokines or the altered metabolism
which results in the depletion from essential nutrients or
the accumulation of immunosuppressive metabolites in the
microenvironment. Metabolites with suppressive activity in-
clude indolamine-2,3-dioxygenase (IDO), arginase, induci-
ble nitric oxide synthetase (iNOS), and lactate dehydroge-
nase (LDH)-A, all repressing the adaptive immune response.
One of the repressive cytokines is TGF-β expressed by a
variety of tumor cells on the cell surface and secreted into
the tumor environment and expressed by repressive immune
cells. CD28 costimulation counteracts repression of T cell
proliferation by TGF-β thereby improving the antitumor
response of redirected T cells [33]. Treg cells inﬁltrating
the tumor mass repress a CAR-redirected T cell antitumor
response [34]. Since Treg cells require IL-2 for survival and
repression eﬀector, T cells equipped with a CAR which is
deﬁcient in inducing CD28-mediated IL-2 secretion exhibit
a superior antitumor response in presence of Treg cells
[35]. Taken together, appropriate costimulation can, at least
partially, counteract tumor-mediated immune repression.
5. In Vitro Evidence for the Efﬁcacy of
CAR-RedirectedTCellstowardB-CLLCells
T cells engineered with a CD19-speciﬁc CAR with CD3ζ
or combined CD28-CD3ζ signalling domain are currently
explored for targeting B-CLL cells. Both CARs can eﬃciently
be expressed on peripheral blood T cells and activate T
cells in a CD19-dependent fashion indicated by increase in
proinﬂammatory cytokines including IFN-γ (Figures 1(a)
and 1(b)). CAR-driven T cell activation is antigen-speciﬁc
since unmodiﬁed T cells or T cells with a CAR of irrelevant
speciﬁcity are not activated upon binding to CD19+ cells. In
contrast to CD3ζ CAR signalling, T cells triggered by the
CD28-CD3ζ CAR, furthermore, secrete IL-2 (Figure 1(c)).
Anti-CD19CARTcellsfromhealthydonorsexhibitcytolytic
activity towards B-CLL cells in vitro (Figure 1(d)). The redi-
rected cytolytic activity in a short term in vitro cytotoxicity
assay is not substantially higher by CD28-CD3ζ compared
to CD3ζ CAR T cells which is in accordance to other reports
usingCARsofdiﬀerentspeciﬁcities[29].Theeﬃcacyinboth
the CD3ζ and CD28-CD3ζ CAR-redirected cytolysis does
not furthermore increase with the level of CD19 expression
on B-CLL cells (Figure 1(e)) implying that the CD19 levels
on B-CLL cells are high enough to cross-link the anti-
CD19 CAR for synapse formation and signalling. Anti-CD19
CAR-modiﬁed T cells, however, do not distinguish between
normal B-cells and B-CLL cells leading to the elimination of
normal B-cells as well (Figure 1(f)).
Peripheral blood T cells from B-CLL patients can be
redirected towards autologous B-CLL cells. CAR-engineered
T cells increase IFN-γ secretion when engaging autologous
B-CLL and additionally secrete IL-2 when stimulated by the
CD28-CD3ζ CAR (Figure 1(g)). Patient’s T cells eﬃciently
lyse autologous B-CLL cells in a short term in vitro assay.
B-CLL cells are resistant to Fas-mediated cell death [36]
rising the question how CAR-engineered T cells execute lysis
of B-CLL cells. Basically, cytolytic T cells can lyse target
cells by a granzyme/perforin-dependent mechanism, which
requires Ca2+ release, via Fas/FasL interaction or via TNF-α.
ThecytolyticactivityofCD19-speciﬁcCARTcellsisblocked
by EGTA while nearly unaltered upon blocking Fas and
TNFα (Figure 2) indicating that cytolysis is predominantly
executed by a granule-dependent pathway to overcome Fas
resistance of B-CLL cells.
High-serum thymidine kinase-1 levels identify a sub-
group of patients with CLL at high risk for disease progres-
sion[37].Thymidinekinase-1isinvolvedinthesalvagepath-
way for DNA synthesis, found in the cytoplasm of dividing
cells and is absent in resting cells [38]. Cycling tumor cells
aremoresusceptibletoaredirectedTcellattackcomparedto
resting cells. Accordingly, B-CLL cells with high proliferative
capacities from patients with high-serum thymidine kinase-
1 levels, that is, >1 0U / L ,a r em o r ee ﬃciently eliminated by
redirected T cells in vitro than B-CLL cells from patients
with low-thymidine kinase-1 levels (Figure 3). Susceptibility
to a CAR-redirected T cell attack is not correlated with other
clinical prognostic factors like mutation of the immunoglob-
ulin heavy chain variable region (IgVH) locus. B-CLL cells in
the population of blood mononuclear cells from patients of
younger age are more eﬃciently eliminated than cells from
>70 year patients. This is likely due to the fact that regulatory
T (Treg) cells increase in numbers in the blood with
progression of the disease and thus with increasing patient’s
age[39].Consequently,depletionfromTregcellsaccordingly
increased T cell-mediated elimination of B-CLL cells.
6. MurineModels Demonstrate Successful
TargetingofCD19+ LeukaemiaCells InVivo
The CAR-redirected T cell response towards CD19+ target
cells was extensively studied in murine models. In most
studies, immunodeﬁcient mice were engrafted with primary
human CD19+ leukaemia cells or cell lines before adoptive
transfer of engineered T cells [36, 40, 41]. Other models use
murine tumor cells which were equipped with the human
target antigen and attacked by engineered murine T cells.4 Advances in Hematology
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Figure 1: Anti-CD19 CAR redirects engineered T-cells towards CD19+ B-CLL cells. (a) Schematic diagram depicting the modular
composition of the recombinant CD19-speciﬁc chimeric antigen receptor (CAR). scFv: single chain fragment of variable region antibody;
IgG1: hinge-CH2CH3 domain of IgG1; TM: transmembrane domain; CD3ζ: intracellular domain of CD3ζ; CD28: intracellular domain of
CD28. (b) Peripheral blood T cells were transduced by retroviral gene transfer to express the respective anti-CD19 CAR. CAR expression was
monitored by ﬂow cytometry upon staining with a FITC-conjugated anti-CD3 antibody and a PE-coupled antihuman IgG1 Fc antibody
directed against the extracellular IgG1 CAR domain. (c) CAR-mediated T-cell activation was monitored by recording IFN-γ and IL-2
secretion upon coincubation of anti-CD19 CAR-engineered T cells (5 ×105 cells/well) with primary CD19+ B-CLL cells (1 ×105 cells/well).
After 24hrs, IFN-γ and IL2 in the coculture supernatant were determined by ELISA. (d) Anti-CD19 CAR-engineered T cells (105 cells/well)
from healthy donors were coincubated with B-CLL cells (105 cells/well), and the viability of B-CLL cells was monitored by a ﬂow cytometry-
based assay after 24hrs. B-CLL cells were identiﬁed by staining for CD5 and CD19, T cells by staining for CD3, dead cells by staining with
7-AAD. The number of viable B-CLL cells was determined using “Rainbow beads” (Becton Dickinson) as standard. Spontaneous cytolysis
is recorded by incubation of B-CLL cells without T cells (−). CAR-redirected cytolysis was calculated in comparison to cytolysis by T cells
without CAR (w/o). (e) The eﬃcacy in speciﬁc cytolysis by anti-CD19 CAR-engineered T cells (data from D) is independent of the CD19
expression level on B-CLL cells as determined by mean ﬂuorescence intensity of CD19 staining. (f) Anti-CD19 CAR-engineered T cells
engineered with anti-CD19 CAR with CD3ζ and CD28-CD3ζ signalling domain, respectively, were incubated with allogeneic peripheral
blood B-cells (purity > 95%) (1×105 cells/well each). B-cells alone (−) and B-cells mixed with un-modiﬁed T cells without CAR (w/o) were
incubated as control. Speciﬁc cytotoxicity towards B-cells was recorded after 24h by a ﬂow cytometry-based assay. T–cells were identiﬁed
by CD3 staining, B-cells by CD5 and CD19 staining, apoptotic cells by 7-AAD staining. (g) CAR-engineered T cells from B-CLL patients
lyse autologous B-CLL cells. T cells from B-CLL patients (n = 3) were engineered with the CD3ζ and CD28-CD3ζ CAR, respectively, both
with speciﬁcity for CD19, and coincubated with autologous CD19+ B-CLL cells (each 1×105 cells/well) for 24hrs. Cytokine release into the
culture supernatant was determined by ELISA. CAR-engineered patient’s T cells showed improved cytotoxicity towards autologous B-CLL
cells, indicated by decrease in B-CLL cell viability, compared to nonmodiﬁed T cells. Data represent the mean ± standard error of mean.
Statistic calculations are based on Student’s t-test; ∗∗ represents P<0.001.6 Advances in Hematology
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Figure 2: CAR-redirected T cells eliminate B-CLL cells pre-
dominantly via granule-mediated cytolysis. Anti-CD19scFv-CD3ζ
CAR T cells were co-incubated (1 × 105 cells/well) with B-CLL
cells (5 × 105 cells/well) in presence of the blocking anti-Fas-
ligand antibody (10μg/mL), the neutralizing anti-TNFα antibody
(10μg/mL), and EGTA (2mM), respectively. Viability of B-CLL
cells was monitored by ﬂow cytometry after 18hrs. As controls, the
neutralizing capacities of the anti-TNF-α and anti-FasL antibodies
were assessed by incubation of sensitive indicator cells with the
respective reagents and antibodies in a cytotoxicity assay (data not
shown).
Although these studies demonstrated the elimination of
malignant cells from immunodeﬁcient mice, they do not
reﬂecttheclinicalsituationoftheimmunocompetentpatient
who is tolerant to CD19 self-antigen and experienced a long
adaptation to the growing tumor cell mass.
A most recently reported model takes these issues into
account [18]. Anti-CD19scFv-CD28-CD3ζ CAR engineered
syngeneic T cells which target murine CD19 were adoptively
transferred to immune competent mice which expressed
CD19 on healthy B-cells and on a transplanted, syngeneic
lymphoma. Along with the antilymphoma activity anti-
CD19 CAR-engineered T cells exhibited profound and
long-lasting activity against healthy CD19+ B-cells without
recovery up to 200 days after adoptive T cell transfer. This
is in accordance with clinical experience where lymphoma
patients treated with anti-CD19 CAR T cells showed lasting
andcompletedepletionofB-cells[42].Intheclinicalcontext,
B-cell depletion is manageable and can, at least partially, be
alleviated by immunoglobulin replacement.
AnalternativemodelwasdescribedbyCheadleetal.[43].
In contrast to the above-described model, T cells were
engineered with a CD3ζ CAR without CD28 costimulatory
domain. CAR-modiﬁed T cells showed a profound anti-
lymphoma eﬀect in the syngeneic mouse accompanied by
temporary depletion of healthy B-cells. Whether the diﬀer-
ence depends on the presence or absence of CD28 costimu-
lation in the context of CAR-mediated T cell activation or on
the diﬀerent CD19-binding domains remains to be explored.
7. Lymphodepletion Improves Antitumor
Efﬁcacy ofRedirectedT-Cells
The immunocompetent mouse model [18], moreover, indi-
cated the crucial role of preconditioning for antilymphoma
eﬃcacy of adoptively transferred T cells. When CAR mod-
iﬁed T cells were transferred into mice without prior total
body irradiation, only marginal antilymphoma activity was
observed with minimal improvement in survival compared
to untreated mice. In contrast, all mice survived when
irradiated prior to adoptive T cell transfer. These and
other data conﬁrm that lymphodepletion before adoptive
T cell therapy is crucial for antitumor eﬃcacy [44, 45].
Increasing preconditioning improves antitumor eﬃcacy of
adoptive T cell therapy [46]. The lymphodepleting regimen
is by itself not suﬃcient to elicit antitumor responses, their
beneﬁt obviously results from the produced environment
which favours persistence and expansion of the adoptively
transferred T cells.
Several mechanisms may contribute to the observation
[47]. T cell homeostasis in number and function under
normopenic conditions in a normal host is tightly controlled
by multiple redundant mechanisms to protect the host from
uncontrolled immune responses against pathogens and from
harmful autoimmunity. Inducing lymphopenia by treatment
with cyclophosphamide and ﬂudarabine or by total body
irradiation is assumed to provide a selective advantage
to adoptively transferred T cells. Nonmyeloablative treat-
ment eliminates regulatory T cells and other repressive
cell populations and eliminates immature dendritic cells
which anergize T cells. Cell populations competing for the
same survival and stimulatory cytokines, like IL-2, IL-7,
IL-15, and IL-21, are eliminated as well (“cytokine sinks”)
which enhances the availability of those factors to adoptively
transferred T cells. Under these conditions of an induced
proinﬂammatory environment adoptively transferred T cells
have selective advantage to undergo homeostatic expansion
and to improve eﬀector functions. In this context, it is
worthwhile to note that the day of adoptive T cell transfer
in relation to preconditioning seems to be crucial since T
cells given at day 2 after stem cell transplantation show
superior ampliﬁcation and persistence than cells given at
later days [48]. Safe nonmyeloablative lymphodepleting
preconditioning protocols are developed and are currently
used in adoptive T cell trials as summarized in Table 1.
Experimental data indicate that increased intensity
lymphoablation by high-dose total body irradiation given
together with haematopoietic stem cell transplantation fur-
ther improves eﬃcacy of adoptive T cell therapy [50]. With
intensiﬁedablation,thelevelsofpro-inﬂammatorycytokines
increased and tumor treatment eﬃcacy improved. Increased
intensity of preconditioning, however, goes against the
current trend in hematopoietic stem cell transplantation to
reducetreatment-relatedadverseeventsbynonmyeloablativeAdvances in Hematology 7
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
S
p
e
c
i
ﬁ
c
c
y
t
o
t
o
x
i
c
i
t
y
(
%
)
S
p
e
c
i
ﬁ
c
c
y
t
o
t
o
x
i
c
i
t
y
(
%
)
S
p
e
c
i
ﬁ
c
c
y
t
o
t
o
x
i
c
i
t
y
(
%
)
Unmutated Mutated
IgVH
.
. ns
<10U/L >10U/L
∗
∗∗ ∗
Thymidine kinase
CD28-CD3ζ CAR CD3ζ CAR
Anti-CEA
CAR
Anti-CEA
CAR
Anti-CD19
CAR
Anti-CD19
CAR
Unmanipulated
Depleted
(a) (b)
(c)
<70y >70y
<70y >70y
<70y >70y
S
p
e
c
i
ﬁ
c
c
y
t
o
t
o
x
i
c
i
t
y
(
%
)
Figure 3: ZAP70-positive B-CLL cells are more eﬃciently eliminated by CAR-redirected T cells in vitro. The eﬃcacy in speciﬁc cytolysis
by CAR-redirected T cells (data from Figure 1(d)) was plotted against (a) serum thymidine kinase-1 levels (<10U/L versus >10U/L), (b)
mutated versus unmutated status of the immunoglobulin heavy chain variable region of B-CLL cells, and (c) patient’s age (<70yrs versus
>70yrs). Closed circles represent CD3ζ CAR, open circles CD28-CD3ζ CAR-mediated B-CLL killing. Depletion from CD25high Treg cells
improves redirected cytolysis of B-CLL cells as exemplarily shown for two patients. Statistic calculations were performed using Student’s
t-test, ∗P<0.05; ∗∗P<0.001.8 Advances in Hematology
Table 1: Phase 1 clinical trials using anti-CD19 CAR modiﬁed T cells for the treatment of B-cell malignancies (updated and adapted from
[49]).
Disease CAR conﬁguration Preconditioning Status of trial Clinical trials.gov
identiﬁer Clinical trial centre
B-CLL scFv-CD28-CD3ζ none versus
cyclophosphamide recruiting NCT00466531
Memorial
Sloan-Kettering
Cancer Center
B-ALL scFv-CD28-CD3ζ none recruiting NCT00709033 Baylor College of
Medicine
B-NHL, B-CLL scFv-CD28-CD3ζ versus
scFv-CD3ζ none recruiting NCT00586391 Baylor College of
Medicine
B-NHL, B-CLL scFv-CD28-CD3ζ versus
EBV/scFv-CD3ζ none recruiting NCT00608270 Baylor College of
Medicine
B-ALL scFv-CD28-CD3ζ cyclophosphamide recruiting NCT01044069
Memorial
Sloan-Kettering
Cancer Center
B-lymphoma, B-CLL scFv-CD28-CD3ζ ﬂudarabine plus
cyclophosphamide recruiting NCT00924326 National Cancer
Institute
B-lymphoma/
leukemia
scFv-41BB-CD3ζ versus
scFv-CD3ζ variable NCT00891215 The University of
Pennsylvania
B-NHL scFv-CD28-CD3ζ BEAM-R NCT00968760 MD Anderson
Cancer Center
refractory B-cell
lymphoma/leukemia scFv-CD3ζ ﬂudarabine plus low
dose cyclophosphamide recruiting The University of
Manchester, UK
strategies. Myeloablation-associated toxicity needs therefore
betitratedagainstthebeneﬁtofimprovedantitumoreﬃcacy.
8.ClinicalTrialswithCAR-Engineered
T Cellsinthe Adoptive Therapy of B-CLL
A panel of anti-CD19 CARs were characterized by means of
laboratory methods during the last decade. Good Manufac-
turing Processes (GMP) conform procedures are established
to modify T cells from the peripheral blood ex vivo with a
CD19-speciﬁc CAR and to subsequently expand engineered
T cells to numbers suﬃcient for adoptive cell therapy [51].
The processes allow generating clinically relevant doses of
CAR-engineered T cells in about 2-3 weeks in a semiclosed
culture system. After expansion, the diversity of the TCR
repertoireispreserved,andtheCD4:CD8Tcellratiodidnot
change or rather increased. Modiﬁcation of T cells by DNA
transfection turned out to be less eﬃcient compared to viral
transduction [52].
CAR-modiﬁed T cells are currently explored in a number
of phase I trials for the therapy of B-CLL and other B-
cell malignancies (Table 1). Patients are receiving CAR-
engineered T cells in advanced stages of the disease, and the
optimal approach is currently being explored, in particular
the optimal dose and the intensity of lymphodepletion [49].
Lessons learnt from pre-clinical animal studies moreover
suggest superior antitumor performance of CD28 and 4-1BB
costimulatory CARs.
Mostseveresideeﬀectsreportedfortrialswithadoptively
transferred CAR T cells were not treatment related; some,
although manageable, required temporary discontinuation
of therapy and protocol modiﬁcation. In a phase I trial,
however, a treatment-related death of an extensively pre-
treated CLL patient occurred shortly after lymphodepletion
and infusion of CD28-CD3ζ C A RTc e l l sa tat o t a ld o s eo f
3×107 Tc ellspe rkg[53].Thepatientwasintheseconddose
escalation cohort. In contrast to patients in the ﬁrst cohort
who received the same number of T cells without developing
signiﬁcant adverse events, this patient was the ﬁrst to receive
cyclophosphamide pretreatment for lymphodepletion. The
syndromes patient developed immediately after T cell trans-
fer are consistent with an inﬂammatory cytokine cascade
afterlymphodepletionwhichgavetheclinicalpictureofrenal
failure and adult respiratory distress syndrome. Although
toxicity did not appear to be directly caused by the modiﬁed
T cells, investigators modiﬁed the protocol by reducing T
cell dose and administering T cells in split doses to improve
safety. Two patients treated on this trial under the modiﬁed
protocol tolerated treatment without notable toxicities.
There is a clear correlation between persistence of modi-
ﬁed T cells and clinical outcome [54]. To improve T cell
persistence, Epstein Barr virus- (EBV-) speciﬁc T cells are
used assumed that those T cells receive optimal and contin-
uous costimulation through their native TCR resulting
in longer survival and redirected cytotoxicity-mediated
through their CAR. Triggered by chronic EBV infection,
CAR-modiﬁed EBV-speciﬁc T cells, like other virus-speciﬁc
T cells, may be superior providing a long-lasting antitumor
response [54]. A recently initiated trial at Baylor College
of Medicine (NCT00608270) aims to address this issue for
the treatment of B-cell malignancies. Alternative strategies
avoiding the need to isolate EBV-speciﬁc T cell clones fromAdvances in Hematology 9
each individual patient are needed to facilitate broad appli-
cation in long term. Application of homeostatic interleu-
kins like IL-7, IL-15, and IL-21 [36, 55, 56] is certainly not
selective in expanding modiﬁed T cells.
T cell persistence, moreover, seems to diﬀer when T cell
clones or polyclonal T cell populations were transferred.
Modiﬁed T cells obtained from limiting dilution procedures
persisted for 1–3 weeks, compared to 5–9 weeks when pa-
tients received T cells from bulk cultures together with low-
dose IL-2 for 14 days [57]. In that trial, modiﬁed T cells
showed indications of eﬃcacy in the treatment of B-cell
lymphoma since two treated patients maintained complete
partial responses, and four patients exhibited stable disease.
9. Challenges for the Targeted
Immunotherapy of B-CLL
9.1. The CAR Design. The impact of the individual CAR
domains on redirected T cell activation was recently dis-
cussed in detail [58]; we here focus on particular issues
related to anti-CD19 CARs. The CAR-targeting domain has
signiﬁcant impact on redirected T cell activation. The anti-
CD19 scFvs currently used are derived from monoclonal
antibodies of diﬀerent aﬃnities targeting diﬀerent epitopes
of CD19. Since both aﬃnity and epitope impact CAR-
mediated T cell activation, the optimal combination needs
to be identiﬁed.
Most binding domains were derived from murine anti-
bodies. The generation of human antimouse antibody re-
sponses was reported in some trials including the generation
of anti-idiotypic antibodies which blocked CAR-mediated
antigen recognition [59, 60]. An antibody immune response
against modiﬁed T cells limits the persistence of modiﬁed T
cells; CARs with humanized domains will therefore be ben-
eﬁcial.
A “spacer” domain between the scFv and the trans-
membrane domain improves binding to antigen by over-
coming steric hindrance in attaining suﬃcient proximity to
the target antigen. Most CARs therefore harbour the human
IgG1 hinge-CH2CH3 region between the scFv and trans-
membrane domain. The same spacer, however, may lead to
nonspeciﬁc activation of eﬀector cells through interaction
with Fc receptors which can be, at least partly, prevented by
a modiﬁed Fc region [61]. Other spacer regions like CD8 can
alternatively be used.
While CAR-redirected T cells clearly exhibit antigen-spe-
ciﬁc and dose-dependent recognition of target cells, engi-
neered T cells sometimes produce small but potentially
crucial amounts of pro-inﬂammatory cytokines, such as
IFN-γ, even when the targeted antigen is absent [62]. A
recent study demonstrates that inactivation of the ﬁrst and
third CD3ζ ITAM decreased non-speciﬁc IFN-γ production
by anti-CD19 CAR-modiﬁed T cells without impairment of
the antileukaemia activity [18]. The FcεRI γ chain which
harbours one ITAM in contrast to the three ITAMs in the
CD3ζ chain may alternatively be used as implied by earlier
studies [63].
“First generation” CARs transmit the signal through the
CD3ζ intracellular chain, “second generation” CARs added
a costimulatory domain like CD28, 4-1BB or OX40 to
improve T cell persistence and activation. While each of
these domains diﬀerentially modulates individual eﬀector
functions [28], the beneﬁt of each costimulation in mount-
ing the antitumor response needs to be determined. This is
moreover required for the most recent “third generation”
CARs with combined costimulatory domains.
9.2. The Eﬀector T-Cell Population. Diﬀerent T cell popula-
tions are currently explored for adoptive cell therapy; it is
still unresolved which T cell subset shows best therapeutic
performance. There is increasing evidence that cytotoxic
eﬀector T cells are not a homogenous population but
consist of diﬀerent subsets with individual phenotypes and
functional capacities. Resting CD8+ T cells in the peripheral
blood exist as na¨ ıve, central memory, and eﬀector memory T
cells. Eﬀector and central memory T cells can be subdivided
on the basis of their expression of homing receptors to
lymphoid organs. Eﬀector memory T cells develop eﬀec-
tor functions more rapidly than central memory T cells,
however, secrete lower amounts of IL-2. In mouse models,
central memory T cells engraft, survive better, and exhibit
superior antitumor activity than eﬀector memory T cells
[64]. Data were conﬁrmed by a study of nonhuman primates
[65]. Central memory T cells can eﬃciently be produced ex
vivo by CD3 and CD28 stimulation which can be further
augmented by IL-7 and IL-15; CD3 stimulation in presence
of IL-2 showed less eﬀective [66].
Na¨ ıve T cells, however, represent the most common
CD8+ T cell phenotype and thereby the major source of
eﬀector cells. Using T cells transgenically or retrovirally,
equippedwithatumor-speciﬁcTCR,[67]revealedthatna¨ ıve
T cell-derived eﬀector cells are superior for proliferation and
cytokine production than eﬀector cells derived from central
memory T cells. Longer persistence of those cells may result
in superior antitumor eﬃcacy compared to central memory
T cells. The procedures for isolating and modifying na¨ ıve
T cells from cancer patients in a GMP-compliant manner,
however, still need to be developed.
CD4+ and CD8+ lymphocytes are most frequently trans-
ferred since a mixture of those T cell subsets performs better
than either T cell subset alone in preclinical models [68].
BulkT cells,however, containregulatory T (Treg)cellswhich
repress the antitumor response [34, 35]. Since CD4+ Tc e l l
depletioneliminateshelperCD4+ TcellsalongwithT regcells
and depleting CD25high T cells also eliminates proliferating
T cells, a more speciﬁc strategy in eliminating Treg cells is
needed.
Issues additionally to be addressed in the near future
include the particular immune status and the decreasing T
cell number in the peripheral blood of patients in advanced
stages of the disease. The eﬃciency in collecting T cells
with suﬃcient functional capacities will be dependent on
the clinical situation in which T cells are collected, that is,
a patient in remission with minimal residual disease versus a
patient with bulk disease. This situation challenges collecting
a d e q u a t en u m b e r so fTc e l l st ob ee x p a n d e d .A p a r tf r o m
that, patients in advanced stages of the disease accumulate a
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activation potential due to decreased CD3ζ expression and
downstream signalling capacities. Engineering with a CD3ζ
or CD28-CD3ζ signalling CAR may overcome some, but
not all defects in “burn-out” T cells of progressed tumor
patients. We assume that T cells in advanced stages of
terminal diﬀerentiation may require additional stimuli to
execute their eﬀector functions. On the other hand, low T
cell counts in patients with advanced disease may limit the
overall eﬃciency in generating engineered T cells with the
consequence that multiple rounds of ex vivo ampliﬁcations
are required to provide clinically eﬀective T cell numbers.
While longer ex vivo stimulation provides higher numbers of
CAR-modiﬁedeﬀectorcells,itremainsquestionablewhether
their antitumor potency and proliferative capacity conserves
with expansion.
Protective immune response seems to be associated with
the ability of adoptively transferred T cells to form memory
[64]. Conditions which promote protective memory after
adoptive T cell transfer need to be established.
Although cytotoxic T cells are extremely eﬀective elim-
inating larger haematopoietic tumor mass and of residual
tumor cells in preclinical model systems, other eﬀector cells
may be envisaged. Beside T cells, NK cells can be eﬀectively
redirected by engineering with CARs [69]. Anti-CD19 CAR
NK cells, modiﬁed by RNA transfer, showed redirected lysis
of CLL cells in vitro [70] providing hope for an alternative
eﬀector cell population in adoptive therapy.
T cells from each individual patient need to be modiﬁed,
ampliﬁed, and tested prior to reinfusion. Local production
at each clinical institution requires individually approved
cell processing facilities and trained personnel to ensure
guideline conform production and the uniformity of the
cell product. From the regulatory point of view, one or few
central facilities may be advantageous which receive cells
from the individual patients and produce the cell product.
Once tested for safety parameters the cell product can be
shipped in a cryopreserved fashion to the clinical site and
locally stored until adoptive transfer to the patient.
9.3. Toxicity. T cells are mostly transduced by retro- or
lentivirus infection to obtain CAR modiﬁed cells with
high eﬃciencies. As far as safety concerns, mutagenesis
by insertion of the CAR encoding transgene needs to be
addressed. There is so far no reported experimental evidence
that retrovirally modiﬁed, mature polyclonal T cells produce
clonal ampliﬁcation upon adoptive transfer [71]. Clinically,
malignant transformation was not observed in any case of
more than 100 patients who were treated so far with gene-
modiﬁed T cells which is in contrast to the treatment with
genetically modiﬁed haematopoietic stem cells. Apart from
that,thesearchforasafervectorsystemusingnonintegrating
vectors [72], RNA transfer [73], or targeted recombination
into safe sites [74] is still ongoing.
Since CD19 targeting is not tumor speciﬁc, CD19+
healthy B-cells are eliminated as well. While this situation
is expected to be clinically manageable, selectivity for
B-CLL cells may be improved by targeting alternative, more
unique surface markers or by simultaneous targeting of
two diﬀerent markers. To improve tumor cell selectivity,
CAR-redirected T cell killing can, moreover, be combined
with the administration of therapeutic antibodies as shown
for the anti-CD20 antibody rituximab which sustains the
antitumoractivityofanti-CD19CARTcellsinthetreatment
of non-Hodgkin’s lymphoma [75].
Once adoptively transferred, controlling engineered T
cell in vivo represents an important option. High-dose
steroids showed eﬀective in eliminating engineered T cells in
ar e c e n ttri a l[ 76]; alternative strategies using tagged receptor
moleculeswhichcanbetargetedbydepletingantibodies[77]
and an inducible caspase-based suicide system [78] showed
eﬃcacy in experimental models.
10.The WayAhead
We think it is quite possible that improvements in all of
these and potentially of additional aspects are required for
success in the T cell therapy of B-CLL in particular and of
malignant diseases in general. Cell dose for minimal toxicity
and maximal antitumor eﬃcacy may be diﬀerent for each
CAR, for each eﬀector cell population, for each precondi-
tioning regimen, and others. The complexity of adoptive cell
therapy challenges standard clinical trial strategies lastingly
established in testing drug-based therapies. At least two
aspects have to be taken into account.
First, a standard in assay systems to monitor cell therapy-
induced immune responses needs to be deﬁned to allow
comparison of data sets from diﬀerent clinical trials.
Second, trials diﬀer in such a large number of parameters
that it will be problematic to identify those aspects which
are critical for the eﬀectiveness or ineﬀectiveness of a
protocol. Table 1 partly illustrates the issue for trials using
CD19 CAR-modiﬁed T cells. To unambiguously identify the
eﬀects of deﬁned changes in clinical trial protocols it will
require systematic “one-parameter trials” on the basis of a
standard format, in particular with respect to conditions
for cell modiﬁcation, a CAR format, the target, and for
preconditioning. The currently recruiting trials using anti-
CD19 CAR modiﬁed T cells give chance for standardizing
and rapidly optimizing the strategy with respect to the
discussed parameters [49]. Although toxicities occurred in
early-phase trials and caution is still warranted, the potential
beneﬁts of adoptive cell therapy with redirected T cells for
the therapy of B-cell malignancies should not be abandoned.
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